

1 **Dengue Viremia Kinetics and Effects on Platelet Count and Clinical Outcomes: An Analysis of 2340**
2 **Patients from Vietnam**

3 **Running title:** Dengue viremia kinetics and effects on outcomes

4 Nguyen Lam Vuong^{1,2*}, Nguyen Than Ha Quyen¹, Nguyen Thi Hanh Tien¹, Duong Thi Hue Kien¹, Huynh
5 Thi Le Duyen¹, Phung Khanh Lam^{1,2}, Dong Thi Hoai Tam¹, Tran Van Ngoc³, Thomas Jaenisch^{4,5}, Cameron
6 P. Simmons^{6,7}, Sophie Yacoub^{1,6}, Bridget A. Wills^{1,6}, Ronald B. Geskus^{1,6*}

7 **Affiliations:**

- 8 1. Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam
9 2. University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam
10 3. Hospital for Tropical Diseases, Ho Chi Minh city, Viet Nam
11 4. Center for Global Health, Colorado School of Public Health, Aurora, CO, USA
12 5. Heidelberg Institute of Global Health (HIGH), Heidelberg University Hospital, Germany
13 6. Centre for Tropical Medicine and Global health, Nuffield Department of Clinical Medicine,
14 University of Oxford, United Kingdom
15 7. World Mosquito Program, Monash University, Clayton, Australia

16 ***Correspondence to:**

17 Dr. Nguyen Lam Vuong (email: vuongnl@oucru.org) or Dr. Ronald B. Geskus (email: rgeskus@oucru.org),
18 Oxford University Clinical Research Unit, Wellcome Trust Africa and Asia Programme, 764 Vo Van Kiet
19 Street, Ward 1, District 5, Ho Chi Minh City, Viet Nam. Telephone: +84 28 39237954 (Ext. 106).

20

21 **Abstract**

22 **Background:** Viremia is a critical factor in understanding the pathogenesis of dengue infection, but
23 limited data exist on viremia kinetics. This study aimed to investigate the kinetics of viremia and its
24 effects on subsequent platelet count, severe dengue, and plasma leakage.

25 **Methods:** We pooled data from three studies conducted in Vietnam between 2000 and 2016, involving
26 2340 dengue patients with daily viremia measurements and platelet counts after symptom onset.
27 Viremia kinetics were assessed using a random effects model that accounted for left-censored data. The
28 effects of viremia on subsequent platelet count and clinical outcomes were examined using a landmark
29 approach with a random effects model and logistic regression model with generalized estimating
30 equations, respectively.

31 **Results:** Viremia levels rapidly decreased following symptom onset, with variations observed depending
32 on the infecting serotype. DENV-1 exhibited the highest mean viremia levels during the first 5-6 days,
33 while DENV-4 demonstrated the shortest clearance time. Higher viremia levels were associated with
34 decreased subsequent platelet counts from day 6 onwards. Elevated viremia levels on each illness day
35 increased the risk of developing severe dengue and plasma leakage. However, the effect size decreased
36 with later illness days.

37 **Conclusions:** This study provides comprehensive insights into viremia kinetics and its effect on
38 subsequent platelet count and clinical outcomes in dengue patients. Our findings underscore the
39 importance of measuring viremia levels during the early febrile phase for dengue studies and clinical
40 practice.

41 **Keywords:** Dengue; Viremia; Platelet; Severe dengue; Plasma leakage

42

43 Introduction

44 Dengue is the most common arboviral infection worldwide and is found mainly in tropical and
45 subtropical areas. The disease has been a growing threat for decades, and in 2019 the World Health
46 Organization (WHO) ranked it among the top 10 threats to global health (World Health Organization,
47 2020). It is estimated that 105 million people are infected by dengue annually, of whom half develop
48 symptoms (Cattarino, Rodriguez-Barraquer, Imai, Cummings, & Ferguson, 2020). Although most
49 infections are asymptomatic or self-limiting, the small proportion of patients who develop complications
50 can still overwhelm health systems in dengue-endemic countries during seasonal epidemics. Climate
51 change, increasing global travel, and urbanization all serve to amplify the distribution of *Aedes aegypti*,
52 the main vector responsible for dengue transmission (Whitehorn & Yacoub, 2019; Yacoub, Kotit, &
53 Yacoub, 2011). Although dengue has been known for centuries, specific treatment is still to be found,
54 and the two licensed vaccines are of limited benefit (Kariyawasam, Lachman, Mansuri, Chakrabarti, &
55 Boggild, 2023; Redoni et al., 2020).

56 Plasma viremia is associated with dengue disease severity (Vuong et al., 2021). Exploring the variation in
57 viremia levels could help improve our understanding of disease pathogenesis and potentially facilitate
58 assessment of new vaccines and treatments for dengue. For example, knowing the natural kinetics of
59 dengue viremia may help in selection of patient groups or timing of antiviral use in therapeutic
60 intervention trials. Dengue viremia kinetics has been investigated in several studies (Ben-Shachar,
61 Schmidler, & Koelle, 2016; Clapham et al., 2016; Clapham, Tricou, Van Vinh Chau, Simmons, & Ferguson,
62 2014; Duyen et al., 2011; Matangkasombut et al., 2020; Nguyet et al., 2013; Simmons, Chau, et al., 2007;
63 Tricou, Minh, Farrar, Tran, & Simmons, 2011). The main findings are: (i) viremia rapidly decreases after
64 symptom onset; (ii) dengue virus (DENV)-1 infection gives higher viremia level than DENV-2 and 3; and
65 (iii) primary infection gives higher viremia than secondary infection in DENV-1. However, these studies
66 had limited sample sizes, particularly for DENV-4 serotype, and did not provide a full account of viremia
67 kinetics. Three studies constructed mechanistic mathematical models and focused on investigating the
68 role of the host immune response in controlling viremia (Ben-Shachar et al., 2016; Clapham et al., 2016;
69 Clapham et al., 2014). Another study assessed viremia in infants aged under 18 months (Simmons, Chau,
70 et al., 2007); the findings cannot be generalized to older children or adults. Others focused on peak
71 viremia level after symptom onset, time to viral clearance and/or the probability of detecting virus on
72 each illness day (Duyen et al., 2011; Matangkasombut et al., 2020; Nguyet et al., 2013; Tricou et al.,

73 2011). In most analyses, viremia levels below the limit of detection were simply set as zero, which may
74 not be appropriate.

75 Quantifying the effect of viremia level on clinical outcomes is important to understand the mechanisms
76 leading to severe disease. We and others have previously found that higher viremia levels are associated
77 with more severe dengue (Duyen et al., 2011; Endy et al., 2004; Morsy et al., 2020; Tang et al., 2010;
78 Tricou et al., 2011; Vaughn et al., 2000; Vuong et al., 2021). However, all analyses were based on a single
79 viremia value per individual. Investigating how individual viremia levels at different times after symptom
80 onset affect the risk of severe outcome potentially provides new insights into pathogenic mechanisms.
81 In addition, the relationship between viremia kinetics and platelet count kinetics – an important
82 hematological indicator – has yet to be investigated.

83 This study aims to improve our understanding of viremia kinetics, how it is associated with patient
84 characteristics and virus serotype, and how it impacts disease severity, using a dataset derived from
85 several thousand individuals with symptomatic dengue. First, we fitted a model for individual viremia
86 kinetics that treats values below the detection limit as censored data, and assessed whether viremia
87 kinetics differed by age, sex, serotype, or immune status. Second, we modeled platelet count kinetics
88 and explored dependence on viremia level. We investigated the potential existence of a lagged effect of
89 viremia, by analyzing platelet counts measured on and following the day of viremia assessment. Third,
90 we modeled the effect of viremia levels, measured at different days after symptom onset, on
91 development of two clinical outcomes, plasma leakage and severe dengue.

92

93 **Methods**

94 ***Study population***


95 We used data from three prospective observational studies performed as part of the longstanding
96 collaboration between the Oxford University Clinical Research Unit (OUCRU) and the Hospital for
97 Tropical Diseases (HTD) in Ho Chi Minh City, Vietnam. Protocol synopses for the three studies are
98 presented in **Appendix 1**. Briefly, studies A and B simultaneously ran from 2000 to 2009 and enrolled
99 children aged between 5 and 15 years. Study A included children with a febrile illness presenting to
100 community outpatient clinics, while study B included children admitted to HTD with a febrile illness
101 suspected to be dengue. Some patients from study A were subsequently enrolled in study B after
102 admission to hospital. Study C ran from 2011 to 2016 and enrolled adults and children presenting with

103 possible dengue within three days of fever onset (IDAMS study, NCT01550016) (Jaenisch et al., 2016).
104 Clinical evaluation and blood sampling were performed daily for all three studies. All studies were
105 approved by the Oxford Tropical Research Ethics Committee and the Institutional Ethics Committee.

106 We identified 3527 laboratory-confirmed dengue patients. Among them, 2340 had relevant data on
107 viremia kinetics and were included in this analysis (**Figure 1**). Details of dengue diagnostics are in
108 **Appendix 2**.

109 **Figure 1. Flowchart illustrating the process of patient selection**

110



111
112

113 @Twenty-two patients in study A lacked viremia data; however, they were subsequently enrolled in study B after
114 hospitalization and had daily viremia measurements.

115 #Although study B spanned from 2000 to 2009, daily viremia levels were only measured between 2006 and 2008.

116 §In study C, one study site in Vietnam did not have daily viremia measurements.

117 Overall, a random sample of 2340 from 3527 laboratory-confirmed dengue patients had data on viremia kinetics.
118 PCR, polymerase chain reaction.

119 ***Plasma viremia measurement and clinical endpoints (details in Appendix 2)***

120 Plasma viremia levels were measured by reverse transcription polymerase chain reaction (RT-PCR),
121 which was an internally controlled, serotype-specific, real-time, two-step assay in studies A and B
122 (Simmons, Popper, et al., 2007), and a one-step procedure using a validated assay in study C (Hue et al.,

123 2011). There was no formal validation of the detection limit for viremia for the two-step PCR used in
124 studies A and B; we set it at 1000 copies/ml. In the one-step PCR used in study C, the detection limit was
125 300 copies/ml for DENV-1 and DENV-3, 60 copies/ml for DENV-2, and 600 copies/ml for DENV-4 (Hue et
126 al., 2011). Patients were classified into probable primary (i.e., the first) or probable secondary (i.e., a
127 second or subsequent) infection based on IgG results on paired samples.

128 For the clinical endpoints we selected severe dengue and plasma leakage. The definitions are based on
129 the WHO 2009 guidelines (World Health Organization, 2009) and standard endpoint definitions for
130 dengue trials (Tomashek et al., 2018). Severe dengue was defined as severe plasma leakage, severe
131 bleeding, and/or severe organ impairment. Plasma leakage included moderate and severe leakage.

132 ***Statistical analysis (details in Appendix 3)***

133 In **Appendix 3-figure 1** we show a directed acyclic graph (DAG) to display assumptions about the causal
134 relationships between variables over illness day. Illness day is the number of days after symptom onset,
135 where day 1 is the day of symptom onset. Potential confounders that needed to be corrected for were
136 age, sex, DENV serotype, and primary/secondary immune status. In all analyses, we used a log-10
137 transformation for viremia levels.

138 We modeled viremia kinetics over time and explored dependence on age, sex, serotype, immune status
139 and PCR method using a linear mixed-effects regression model, allowing for left censored values in the
140 outcome variable. In the fixed effect, we allowed for interactions between serotype and immune status,
141 and between illness day and all other covariates. Nonlinear trends by age and illness day were
142 investigated using splines with three and four knots, respectively. We included a random effect with an
143 intercept and splines for illness day with four knots to model the intra-person correlation. Due to the
144 presence of a left-skewed distribution in log-10 viremia (**Appendix 4-figure 1**), a sensitivity analysis was
145 conducted using the 10th-root transformation.

146 Platelet counts were transformed using a fourth-root transformation since the distribution was right-
147 skewed (**Appendix 4-figure 2**). The effect of viremia on subsequent platelet count was investigated using
148 the landmark approach (van Houwelingen & Putter, 2011). For each illness day from 1 to 7, a landmark
149 dataset was created, which included viremia on that day, platelet count from that day to day 10, and the
150 time-fixed variables (age, sex, serotype, immune status, and PCR method). For the supermodel that
151 combined all landmark datasets, we used a linear mixed effects model including viremia, age, sex,
152 serotype, immune status, PCR method, illness day and landmark. In the fixed effect, we also included
153 four-way interactions between viremia, serotype, PCR method and a) and immune status, b) illness day,

154 and c) landmark day. Splines with three knots were used to allow for nonlinear trends in log-10 viremia,
155 age, illness day, and landmark day. We included a random effect with an intercept by the combination
156 of individuals and landmark, and splines for illness day with three knots.

157 The effect of viremia on clinical endpoints was investigated using a logistic regression model using the
158 landmark approach (van Houwelingen & Putter, 2011). For each illness day from 1 to 7, a landmark
159 dataset was created, which included viremia on that day, occurrence of the endpoint on or after that
160 day, and the time-fixed variables similar to above. All individuals who had already experienced the
161 relevant endpoint before that day were excluded. We fitted a logistic regression model for each
162 landmark dataset and then fitted a supermodel that combined all the datasets. For the supermodel we
163 used generalized estimating equations (GEE) to account for repeated inclusion of individuals at multiple
164 landmarks. We included viremia, age, sex, serotype, immune status, study, and landmark day, and
165 allowed for the four-way interaction between viremia, serotype, immune status and landmark day, and
166 two-way interactions between viremia and all other covariates. Splines were used to allow for nonlinear
167 trends in log-10 viremia (three knots), age (three knots), and landmark (three knots). Since plasma
168 leakage had missing data, we performed an analysis with imputed data using multiple imputation by
169 chained equations (MICE). The imputation was done in our previous study (Vuong et al., 2021).

170 In the analyses for platelet count and clinical outcomes, undetectable viremia levels were set as the
171 specific detection limits, and a binary dummy variable (yes/no) was created to indicate whether the
172 viremia value was undetectable. Since the individual spline terms are hard to interpret and the large
173 data set makes most differences statistically significant, results are primarily reported using plots of
174 predicted values. All analyses were done using the statistical software R version 4.1.0 (R Core Team,
175 2021) with 'MCMCglmm' (Hadfield, 2010), 'lme4' (Bates, Maechler, Bolker, & Walker, 2015), 'geepack'
176 (Halekoh, Højsgaard, & Yan, 2006), and 'rms' (Harrell Jr, 2021) packages for the models.

177

178 **Results**

179 Baseline characteristics and outcomes are summarized in **Table 1**. Three quarters of the participants
180 were children, and male sex predominated (60%). Most patients (85%) were enrolled on illness day 2 or
181 3. All four serotypes were included, but DENV-1 was the most prevalent (54%). Most infections (69%)
182 were classified as probable secondary infection, while in 11% immune status could not be determined.
183 There were 353 patients (15%) with plasma leakage and 65 patients (3%) with severe dengue. In
184 **Appendix 4-table 1** we summarize plasma leakage and severe dengue by serotype and immune status.

185 DENV-2 had the highest proportion of these two outcomes. Patients with probable secondary infection
 186 were more likely to experience these outcomes than those with probable primary infection or
 187 indeterminate immune status, regardless of the infecting serotype.

188 **Table 1. Baseline characteristics and clinical outcomes**

	N ^a	All patients (N=2340)	Study A (N=363)	Study B (N=622)	Study C (N=1355)
Age, years	2340	13 (10; 18)	12 (9; 14)	12 (10; 13)	16 (10; 25)
Sex male	2340	1403 (60)	195 (54)	412 (66)	796 (59)
Illness day at enrolment	2340				
1		310 (13)	59 (16)	7 (1)	244 (18)
2		848 (36)	150 (41)	155 (25)	543 (40)
3		1137 (49)	114 (31)	455 (73)	568 (42)
4		45 (2)	40 (11)	5 (1)	0 (0)
Serotype	2340				
DENV-1		1264 (54)	233 (64)	410 (66)	621 (46)
DENV-2		373 (16)	48 (13)	130 (21)	195 (14)
DENV-3		252 (11)	80 (22)	82 (13)	90 (7)
DENV-4		451 (19)	2 (1)	0 (0)	449 (33)
Immune status	2340				
Probable primary		474 (20)	134 (37)	124 (20)	216 (16)
Probable secondary		1619 (69)	219 (60)	464 (75)	936 (69)
Indeterminate		247 (11)	10 (3)	34 (5)	203 (15)
Plasma leakage	2288	353 (15)	43 (13)	177 (29)	133 (10)
Missing		52	39	13	0
Illness day of plasma leakage	327				
3		2 (1)	0 (0)	0 (0)	2 (2)
4		71 (22)	12 (30)	35 (23)	24 (18)
5		107 (33)	12 (30)	50 (32)	45 (34)
6		105 (32)	12 (30)	49 (32)	44 (33)
7		42 (13)	4 (10)	20 (13)	18 (14)
Missing		26	3	23	0
Severe dengue	2340	65 (3)	6 (2)	40 (6)	19 (1)
Illness day of severe dengue	65				
3		2 (3)	0 (0)	2 (5)	0 (0)
4		13 (20)	0 (0)	12 (30)	1 (5)
5		24 (37)	2 (33)	16 (40)	6 (32)
6		20 (31)	4 (67)	7 (18)	9 (47)
7		6 (9)	0 (0)	3 (8)	3 (16)

189 ^a N represents the number of patients with available data (i.e., without missing data).


190 Summary statistics are number of patients (%) or median (25th; 75th percentiles).

191 DENV, dengue virus

192 *Viremia kinetics and the relationship with clinical characteristics*

193 Individual viremia trajectories are shown in **Figure 2**. Most individuals had a decreasing trend from day 1
 194 or 2 onwards. However, values higher than the baseline value were observed up to day 7 (**Appendix 4-**
 195 **figure 3**). The decreasing trend was consistent across all combinations of serotype and immune status
 196 (**Figure 2**).


197 **Figure 2. Individual trajectories of measured viremia levels**



198 The dots represent the measured viremia levels and are connected by lines for each individual patient. The dashed
199 lines indicate the detection limits, which are 300 copies/ml for DENV-1 and DENV-3, 60 copies/ml for DENV-2, and
200 600 copies/ml for DENV-4 in the one-step PCR cohort, and 1000 copies/ml in the two-step PCR cohort. 57
201 measured values that are lower than 1000 copies/ml in the two-step PCR cohort are considered as below the
202 detection limit. Values below the detection limit are visually represented as 1/10 of the corresponding detection
203 limit (on the original scale). DENV, dengue virus; PCR, polymerase chain reaction.
204

205 In **Figure 3** we present the fitted values based on the model for viremia for the one-step PCR cohort. The
206 mean viremia trajectory differed by serotype. DENV-1 gave the highest viremia levels, with DENV-2 in
207 secondary infection giving similar levels from day 5 onwards. DENV-2, DENV-3 and DENV-4 had similar
208 viremia levels during the first three days. However, viremia decreased rapidly in DENV-4, reaching
209 undetectable levels in the shortest time, while DENV-2 showed the slowest decline. These differences
210 between serotypes were more pronounced in case of probable primary infection (**Figure 3-A**). In terms
211 of immune status, probable primary infection showed higher viremia levels compared to probable
212 secondary infection in DENV-1 from day 3 onwards. The disparity between probable primary and
213 probable secondary infection was less pronounced in the other serotypes (**Figure 3-B**). Mean viremia
214 levels were comparable between females and males (**Figure 3-C**), as well as across age (**Figure 3-D**). The
215 one-step PCR method resulted in longer viremia compared to the two-step PCR (**Appendix 5-figure 1**).
216 The sensitivity analysis using the 10th-root transformation of viremia gave results similar to the main
217 analysis using log-10 viremia (**Appendix 5-figure 2**).

218 **Figure 3. Fitted trends in mean viremia levels**




219
 220 The colored lines represent the estimated mean viremia levels, and the colored shaded regions represent the
 221 corresponding 95% credible intervals. The horizontal lines represent the detection limits (D1, D2, D3, and D4
 222 denote DENV-1, DENV-2, DENV-3, and DENV-4, respectively). Dashed lines indicate fitted viremia levels that are
 223 below the detection limit. Viremia levels are shown for age of 10 years, male sex, serotype DENV-1, probable
 224 secondary infection, and using the one-step PCR. DENV, dengue virus; PCR, polymerase chain reaction.
 225

226

227 ***Effect of viremia on subsequent platelet count***

228 **Figure 4** shows the mean platelet counts by viremia levels based on the supermodel for the one-step
229 PCR method. There was minimal impact of viremia on days 1-5 platelet count. However, higher viremia
230 levels gave decreased subsequent platelet counts from day 6 onwards, for all serotypes. The strength of
231 this effect increased with later illness day and was more pronounced in DENV-1 and DENV-2 compared
232 to DENV-3 and DENV-4. The effect of viremia on subsequent platelet count remained consistent across
233 subgroups of immune status, sex, and age. In the two-step PCR cohort, the effect of viremia on platelet
234 count was less pronounced compared to the one-step PCR cohort, although the overall trends were
235 similar (**Appendix 6-figure 1**).

236 **Figure 4. Fitted trends in mean platelet counts according to viremia levels – results from the supermodel**




237
 238 The colored lines or dots represent the estimated mean platelet counts. The colored shaded regions and whiskers indicate the corresponding 95% confidence
 239 intervals. Each row represents the effect of viremia on a specific day to platelet count from that day to day 10. No fitted trends are made for DENV-4 in LM day
 240 7 since viremia was undetectable in almost all DENV-4 cases from day 7 onwards. The mean platelet counts are shown for age of 10 years, male sex, probable
 241 secondary infection, and using the one-step PCR. DENV, dengue virus; LM, landmark; PCR, polymerase chain reaction; U, under the limit of detection.

242 ***Effect of viremia on clinical outcomes***

243 Higher viremia levels increased the risk of severe dengue and plasma leakage for each of the serotypes
244 (**Figure 5**). The effect of viremia on both endpoints decreased with later landmark day of viremia
245 measurement, particularly for severe dengue (**Appendix 7-table 1**). However, these trends were not
246 clear in the results obtained from the simple logistic regression models at each landmark time point
247 (**Appendix 7-figure 1**). This trend remained consistent across subgroups of sex, age, and study
248 (**Appendix 7-figure 2**). Furthermore, the results were consistent between the analyses with and without
249 imputation (**Figure 5**).

250 The supermodel revealed that older individuals had a relatively lower risk of developing severe dengue,
251 but the trend was not significant. Males exhibited a slightly higher risk of severe dengue compared to
252 females. The effect of serotype on the two endpoints was dependent on immune status. Individuals with
253 probable secondary infection had a higher risk of experiencing both endpoints compared to those with
254 probable primary infection (**Appendix 7-figure 3**).

255 **Figure 5. Probability of occurrence of the two clinical endpoints according to viremia levels –**
 256 **results from the supermodel**



257 The colored lines or dots represent the probability of the endpoints. The colored shaded regions and whiskers
 258 indicate the corresponding 95% confidence intervals. Each column represents the effect of viremia on a specific
 259 day. No fitted trends are made for DENV-4 in LM day 7 since viremia was undetectable in almost all DENV-4 cases
 260 from day 7 onwards. The probabilities are shown for age of 10 years, male sex, probable secondary infection, and
 261 from Study C. DENV, dengue virus, LM, landmark; PCR, polymerase chain reaction; U, under the limit of detection.
 262
 263

264 Discussion

265 In this study, we conducted a comprehensive analysis using a large dataset of 2340 viremic dengue
266 patients to examine viremia kinetics from first presentation, its association with various virus and
267 patient characteristics, and its impact on subsequent platelet count and disease severity. As others have
268 described, we found that plasma viremia declines rapidly following the onset of symptoms, with the
269 kinetics primarily influenced by the specific infecting serotype. Moreover, higher viremia levels were
270 associated with a decrease in subsequent platelet count from day 6 onwards. Elevated viremia levels
271 were found to increase the risk of developing severe dengue and plasma leakage, with the effect
272 becoming weaker at later days. The effects of viremia on platelet count and clinical outcomes did not
273 differ much by different subgroups of serotype, immune status, age, and sex.

274 There is a limited number of published papers that studied the individual trajectory of dengue viremia.
275 Most used data from Vietnam (Ben-Shachar et al., 2016; Clapham et al., 2016; Clapham et al., 2014;
276 Duyen et al., 2011; Nguyet et al., 2013; Simmons, Chau, et al., 2007; Tricou et al., 2011), while one was
277 from Thailand (Matangkasombut et al., 2020). Our study has provided further evidence supporting
278 previous findings. We confirmed that (i) viremia rapidly decreases following the onset of symptoms, (ii)
279 DENV-1 exhibits higher viremia levels and a longer duration of detectability compared to DENV-2 and
280 DENV-3, and (iii) primary infection is associated with higher and more prolonged detectable viremia
281 than secondary infection in DENV-1, while this pattern was not consistent across other serotypes. We
282 have added viremia kinetics of DENV-4, and showed that viremia levels declined more rapidly than the
283 other serotypes. Furthermore, our study demonstrated that the new PCR test has the ability to detect
284 plasma viremia for a longer period compared to the older test. This may be attributed to the lower
285 detection limits of the new test. Explaining the differences in viremia kinetics between serotypes
286 remains challenging, as the molecular factors of the virus that influence plasma viremia levels are still
287 unknown. It is also important to note that our study focused on the time since symptom onset rather
288 than the time since infection. We cannot rule out that some of the observed differences are explained
289 by a difference in time from infection to symptom onset.

290 Our study suggests that higher viremia levels on any day before day 6 are associated with reduced
291 platelet count on days 6-8, typically corresponding to the nadir of platelet count. Additionally, it is
292 possible that viremia in the initial four days after symptom onset could affect platelet count with a delay
293 of 3-4 days. The direct involvement of the dengue virus in triggering platelet activation and apoptosis
294 can contribute to the development of thrombocytopenia. Thrombocytopenia in dengue infection is

295 thought to occur through two mechanisms: bone marrow suppression, which reduces thrombopoiesis,
296 and increased peripheral platelet clearance (Quirino-Teixeira, Andrade, Pinheiro, Rozini, & Hottz, 2021).
297 Various processes contribute to these mechanisms, including platelet-leukocyte and platelet-endothelial
298 cell interactions, phagocytosis, complement-mediated lysis, aggregation, and clot formation.
299 Additionally, several host immune response factors are involved in platelet activation (Balakrishna Pillai,
300 Chu, Mariappan, & JeanPierre, 2021). In our analysis, we considered interactions between viremia level
301 and both serotype as well as immune status. Interestingly, we observed that the effect of viremia level
302 on subsequent platelet count did not differ much by serotype and immune status.

303 Higher plasma viremia levels increase the risk of worse clinical outcomes, as demonstrated in our
304 previous study that only utilised viremia at enrollment during the febrile phase (Vuong et al., 2021). The
305 diminishing impact of viremia on the two endpoints on later illness days may be attributed to the
306 heightened immune responses that are likely triggered by higher viremia levels, and the resulting
307 complex interplay between these factors that underlies progression to severe dengue. The effects of
308 viremia, age, serotype, immune status, and illness day on the clinical endpoints in this study are
309 consistent with those observed in the previous study. The similarity between these two analyses, along
310 with the weaker effect of viremia at later days, suggests that viremia levels around the time of symptom
311 onset could serve as a reliable predictor of dengue severity. It suggests that the early febrile phase,
312 specifically illness day 1-3, is the critical period of measuring viremia levels in clinical practice and
313 dengue studies. Secondary infection remains a substantial risk factor for more severe outcomes, while
314 viremia kinetics are not influenced much by immune status. These findings suggest that immune status
315 and viremia may be independent predictors of clinical outcomes, following distinct pathways.

316 The landmark approach enabled us to investigate the effect of viremia on platelet count and the clinical
317 endpoints at each illness day, ranging from day 1 to 7, while ensuring that the viremia measurements
318 preceded the occurrence of the outcomes. The supermodel allows for investigation of trends of the
319 effects, while gaining power because we assume the effects of some fixed factors (e.g., age and sex) to
320 remain constant over time. There might be other potential confounders such as host genetic and
321 immune response factors, but these data were not available. Moreover, we assumed that the relation
322 between viremia level and platelet count was one-way: viremia level affects platelet count. Whether
323 platelet count affects viremia is unknown.

324 A notable strength of our study is the utilization of a large pooled dataset, which allowed for a flexible
325 modeling approach to investigate the influence of age, sex, serotype, and immune status, as well as

326 their interactions and nonlinear trends. The use of a model that accounts for left-censored data was
327 needed for capturing the distribution of viremia levels, considering the significant proportion of
328 undetectable values observed.

329 The study has several limitations. Firstly, the study only included patients from Vietnam, which may
330 restrict the generalisability of the findings to other countries and regions. Secondly, our study assessed
331 viral RNA in the plasma, including both viable and non-viable viral particles, which could potentially lead
332 to an overestimation of the infectious viral particles in the blood. Lastly, data during the incubation
333 period were unavailable as patients are typically not diagnosed with dengue until symptom onset.
334 Therefore, the trajectory of viremia from the time of infection onwards could not be demonstrated, and
335 symptom onset was used as the reference point instead of infection. This could potentially lead to an
336 inaccurate interpretation of the results if the incubation period is influenced by the same factors that we
337 included in our analyses. For example, in cases of secondary infection, the immune response is stronger
338 and quicker than in primary infection. This might lead to a shorter duration between infection and
339 symptom onset, as well as faster viral clearance.

340 In conclusion, our findings reveal that viremia levels exhibit a rapid decline shortly after symptom onset,
341 becoming undetectable after approximately one week in the majority of patients. Viremia kinetics
342 display variations depending on the infecting serotype. Higher viremia levels are associated with a
343 subsequent reduction in platelet count on illness days 6-8, and an increased risk of experiencing more
344 severe clinical outcomes. Viremia serves as an important predictor of dengue outcomes, independent of
345 the host immune status. However, when considering our previous analysis that involved single early
346 viremia measurements, the addition of daily viremia measurements may not enhance the prediction of
347 worse clinical outcomes. Thus, the measurement of viremia levels during the early febrile phase is an
348 important marker for clinical practice and dengue-related research.

349 **Acknowledgements**

350 We thank the staff from the Dengue group at the Oxford University Clinical Research Unit, Hospital for
351 Tropical Diseases at Ho Chi Minh City (Vietnam) and the many hospitals and clinics who recruited and
352 followed patients in the three studies. We gratefully acknowledge the patients and their relatives for
353 participating in these studies.

354

355 **Additional information**

356 ***Competing interests***

357 Thomas Jaenisch: reports receiving personal fees as members of the Roche Pharmaceuticals Advisory
358 Board on Severe Dengue, outside the submitted work.

359 Sophie Yacoub: reports receiving personal honorarium for attending the Novartis dengue drug ad board
360 meeting and Takeda dengue education symposium, outside the submitted work.

361 Bridget Wills: reports receiving personal fees a) as a member of the Roche Advisory Board on Severe
362 Dengue and b) as a member of the Data Monitoring and Adjudication Committees for the Takeda
363 dengue vaccine trials, both outside the remit of the submitted work.

364 The other authors declare that no competing interests exist.

365 ***Funding***

Funder	Grant reference number	Author
Wellcome Trust	084368/Z/07/Z	Cameron P. Simmons
Wellcome Trust	077078/Z/05/Z 077078/Z/05/A 089276/B/09/Z	Bridget A. Wills
European Union Seventh Framework Programme	FP7-281803 IDAMS	Thomas Jaenisch
Wellcome Trust	106680/Z/14/Z	Ronald B. Geskus Sophie Yacoub
Wellcome Trust	225167/Z/22/Z	Ronald B. Geskus Sophie Yacoub

366 The funders had no role in study design, data collection and interpretation, or the decision to submit the
367 work for publication.

368 **Author contributions**

369 Nguyen Lam Vuong: Conceptualization, Methodology, Software, Formal analysis, Data curation, Writing-
370 original draft, Writing-review & editing, Visualization

371 Nguyen Than Ha Quyen: Investigation, Resources, Writing-review & editing

372 Nguyen Thi Hanh Tien: Investigation, Resources, Writing-review & editing

373 Duong Thi Hue Kien: Investigation, Resources, Writing-review & editing

374 Huynh Thi Le Duyen: Investigation, Resources, Writing-review & editing

375 Phung Khanh Lam: Methodology, Investigation, Resources, Data curation, Writing-review & editing,
376 Supervision

377 Dong Thi Hoai Tam: Conceptualization, Investigation, Resources, Writing-review & editing

378 Tran Van Ngoc: Conceptualization, Investigation, Resources, Writing-review & editing

379 Thomas Jaenisch: Conceptualization, Methodology, Investigation, Writing-review & editing, Funding
380 acquisition

381 Cameron P. Simmons: Conceptualization, Methodology, Investigation, Writing-review & editing, Funding
382 acquisition

383 Sophie Yacoub: Conceptualization, Methodology, Investigation, Writing-review & editing, Supervision,
384 Funding acquisition

385 Bridget A. Wills: Conceptualization, Methodology, Investigation, Writing-review & editing, Supervision,
386 Funding acquisition

387 Ronald B. Geskus: Conceptualization, Methodology, Investigation, Writing-review & editing, Supervision,
388 Funding acquisition

389 **Ethics**

390 Human subjects: The studies and the blood sample analysis were approved by the Scientific and Ethics
391 Committees of all study sites and by the Oxford Tropical Research Ethics Committee (OxTREC Ref No
392 017-02; 012-05; and 502-18).

393

394 **References**

- 395 Balakrishna Pillai, A. K., Chu, J. J. H., Mariappan, V., & JeanPierre, A. R. (2021). Platelets in the
396 pathogenesis of flavivirus disease. *Curr Opin Virol*, 52, 220-228.
397 doi:10.1016/j.coviro.2021.12.007
- 398 Bates, D., Maechler, M., Bolker, B., & Walker, S. (2015). Fitting Linear Mixed-Effects Models Using lme4.
399 *Journal of Statistical Software*, 67(1), 1-48. doi:10.18637/jss.v067.i01
- 400 Ben-Shachar, R., Schmidler, S., & Koelle, K. (2016). Drivers of Inter-individual Variation in Dengue Viral
401 Load Dynamics. *PLoS Comput Biol*, 12(11), e1005194. doi:10.1371/journal.pcbi.1005194
- 402 Cattarino, L., Rodriguez-Barraquer, I., Imai, N., Cummings, D. A. T., & Ferguson, N. M. (2020). Mapping
403 global variation in dengue transmission intensity. *Sci Transl Med*, 12(528).
404 doi:10.1126/scitranslmed.aax4144
- 405 Clapham, H. E., Rodriguez-Barraquer, I., Azman, A. S., Althouse, B. M., Salje, H., Gibbons, R. V., . . .
406 Cummings, D. A. (2016). Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After
407 Symptomatic Primary and Postprimary DENV Infection. *J Infect Dis*, 213(9), 1428-1435.
408 doi:10.1093/infdis/jiv759
- 409 Clapham, H. E., Tricou, V., Van Vinh Chau, N., Simmons, C. P., & Ferguson, N. M. (2014). Within-host viral
410 dynamics of dengue serotype 1 infection. *J R Soc Interface*, 11(96). doi:10.1098/rsif.2014.0094
- 411 Duyen, H. T., Ngoc, T. V., Ha do, T., Hang, V. T., Kieu, N. T., Young, P. R., . . . Wills, B. A. (2011). Kinetics of
412 plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential
413 effects according to serotype and immune status. *J Infect Dis*, 203(9), 1292-1300.
414 doi:10.1093/infdis/jir014
- 415 Endy, T. P., Nisalak, A., Chunsuttitwat, S., Vaughn, D. W., Green, S., Ennis, F. A., . . . Libraty, D. H. (2004).
416 Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity
417 of disease in a prospective cohort study of DV infection in Thailand. *J Infect Dis*, 189(6), 990-
418 1000. doi:10.1086/382280
- 419 Hadfield, J. D. (2010). MCMC Methods for Multi-Response Generalized Linear Mixed Models: The
420 MCMCglmm R Package. *Journal of Statistical Software*, 33(2), 1 - 22. doi:10.18637/jss.v033.i02
- 421 Halekoh, U., Højsgaard, S., & Yan, J. (2006). The R Package geepack for Generalized Estimating
422 Equations. *Journal of Statistical Software*, 15/2, 1-11.

- 423 Harrell Jr, F. E. (2021). rms: Regression Modeling Strategies. R package version 6.2-0. Retrieved from
424 <https://CRAN.R-project.org/package=rms>
- 425 Hue, K. D., Tuan, T. V., Thi, H. T., Bich, C. T., Anh, H. H., Wills, B. A., & Simmons, C. P. (2011). Validation of
426 an internally controlled one-step real-time multiplex RT-PCR assay for the detection and
427 quantitation of dengue virus RNA in plasma. *J Virol Methods*, *177*(2), 168-173.
428 doi:10.1016/j.jviromet.2011.08.002
- 429 Jaenisch, T., Tam, D. T., Kieu, N. T., Van Ngoc, T., Nam, N. T., Van Kinh, N., . . . Wills, B. (2016). Clinical
430 evaluation of dengue and identification of risk factors for severe disease: protocol for a
431 multicentre study in 8 countries. *BMC Infect Dis*, *16*, 120. doi:10.1186/s12879-016-1440-3
- 432 Kariyawasam, R., Lachman, M., Mansuri, S., Chakrabarti, S., & Boggild, A. K. (2023). A dengue vaccine
433 whirlwind update. *Ther Adv Infect Dis*, *10*, 20499361231167274.
434 doi:10.1177/20499361231167274
- 435 Matangkasombut, P., Manopwisedjaroen, K., Pitabut, N., Thaloengsok, S., Suraamornkul, S.,
436 Yingtaweesak, T., . . . Singhasivanon, P. (2020). Dengue viremia kinetics in asymptomatic and
437 symptomatic infection. *Int J Infect Dis*, *101*, 90-97. doi:10.1016/j.ijid.2020.09.1446
- 438 Morsy, S., Hashan, M. R., Hieu, T. H., Mohammed, A. T., Elawady, S. S., Ghosh, P., . . . Huy, N. T. (2020).
439 The association between dengue viremia kinetics and dengue severity: A systemic review and
440 meta-analysis. *Rev Med Virol*, *30*(6), 1-10. doi:10.1002/rmv.2121
- 441 Nguyet, M. N., Duong, T. H., Trung, V. T., Nguyen, T. H., Tran, C. N., Long, V. T., . . . Simmons, C. P. (2013).
442 Host and viral features of human dengue cases shape the population of infected and infectious
443 *Aedes aegypti* mosquitoes. *Proc Natl Acad Sci U S A*, *110*(22), 9072-9077.
444 doi:10.1073/pnas.1303395110
- 445 Quirino-Teixeira, A. C., Andrade, F. B., Pinheiro, M. B. M., Rozini, S. V., & Hottz, E. D. (2021). Platelets in
446 dengue infection: more than a numbers game. *Platelets*, 1-8.
447 doi:10.1080/09537104.2021.1921722
- 448 R Core Team. (2021). A language and environment for statistical computing. Retrieved from R
449 Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>
- 450 Redoni, M., Yacoub, S., Rivino, L., Giacobbe, D. R., Luzzati, R., & Di Bella, S. (2020). Dengue: Status of
451 current and under-development vaccines. *Rev Med Virol*, *30*(4), e2101. doi:10.1002/rmv.2101

- 452 Simmons, C. P., Chau, T. N., Thuy, T. T., Tuan, N. M., Hoang, D. M., Thien, N. T., . . . Farrar, J. (2007).
453 Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. *J Infect Dis*,
454 *196*(3), 416-424. doi:10.1086/519170
- 455 Simmons, C. P., Popper, S., Dolocek, C., Chau, T. N., Griffiths, M., Dung, N. T., . . . Farrar, J. (2007).
456 Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients
457 with acute dengue hemorrhagic fever. *J Infect Dis*, *195*(8), 1097-1107. doi:10.1086/512162
- 458 Tang, Y., Kou, Z., Zhang, F., Yao, X., Liu, S., Ma, J., . . . Jin, X. (2010). Both viremia and cytokine levels
459 associate with the lack of severe disease in secondary dengue 1 infection among adult Chinese
460 patients. *PLoS One*, *5*(12), e15631. doi:10.1371/journal.pone.0015631
- 461 Tomashek, K. M., Wills, B., See Lum, L. C., Thomas, L., Durbin, A., Leo, Y. S., . . . Gubler, D. J. (2018).
462 Development of standard clinical endpoints for use in dengue interventional trials. *PLoS Negl*
463 *Trop Dis*, *12*(10), e0006497. doi:10.1371/journal.pntd.0006497
- 464 Tricou, V., Minh, N. N., Farrar, J., Tran, H. T., & Simmons, C. P. (2011). Kinetics of viremia and NS1
465 antigenemia are shaped by immune status and virus serotype in adults with dengue. *PLoS Negl*
466 *Trop Dis*, *5*(9), e1309. doi:10.1371/journal.pntd.0001309
- 467 van Houwelingen, H., & Putter, H. (2011). *Dynamic prediction in clinical survival analysis*: CRC Press.
- 468 Vaughn, D. W., Green, S., Kalayanarooj, S., Innis, B. L., Nimmannitya, S., Suntayakorn, S., . . . Nisalak, A.
469 (2000). Dengue viremia titer, antibody response pattern, and virus serotype correlate with
470 disease severity. *J Infect Dis*, *181*(1), 2-9. doi:10.1086/315215
- 471 Vuong, N. L., Quyen, N. T. H., Tien, N. T. H., Tuan, N. M., Kien, D. T. H., Lam, P. K., . . . Wills, B. A. (2021).
472 Higher Plasma Viremia in the Febrile Phase Is Associated With Adverse Dengue Outcomes
473 Irrespective of Infecting Serotype or Host Immune Status: An Analysis of 5642 Vietnamese
474 Cases. *Clin Infect Dis*, *72*(12), e1074-e1083. doi:10.1093/cid/ciaa1840
- 475 Whitehorn, J., & Yacoub, S. (2019). Global warming and arboviral infections. *Clin Med (Lond)*, *19*(2), 149-
476 152. doi:10.7861/clinmedicine.19-2-149
- 477 World Health Organization. (2009). *Dengue: guidelines for diagnosis, treatment, prevention and control*:
478 World Health Organization.
- 479 World Health Organization. (2020). Ten threats to global health in 2019. Retrieved from
480 <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>

481 Yacoub, S., Kotit, S., & Yacoub, M. H. (2011). Disease appearance and evolution against a background of
482 climate change and reduced resources. *Philos Trans A Math Phys Eng Sci*, 369(1942), 1719-1729.
483 doi:10.1098/rsta.2011.0013
484